Degradable, drug-eluting stents: A new frontier for the treatment of coronary artery disease

Expert Review of Medical Devices

Volumn 2, Issue 6, 2005, Pages 667-671

  Kohn, Joachim ^a   Zeltinger, Joan ^b  

^a RUTGERS UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Coronary artery; Degradable; Polymer; Stent; Tyrosine derived polycarbonate

Indexed keywords

COPOLYMER; GROWTH FACTOR; MAGNESIUM; METAL; POLYCAPROLACTONE; POLYCARBONATE; POLYHYDROXYALKANOIC ACID; POLYLACTIC ACID; POLYMER;

BIODEGRADABLE IMPLANT; BIOMEDICAL TECHNOLOGY ASSESSMENT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EQUIPMENT DESIGN; FLUOROSCOPY; HUMAN; IN-STENT RESTENOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOSENSITIVITY; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; VISIBILITY; X RAY;

EID: 28244493509     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2.6.667     Document Type: Review

References (29)

1. American Heart Association. Heart and Stroke Statistical Update. American Heart Association, TX, USA (2001).
2. Zimmer S, Jacobs B, Levy T, Robins J. Med Tech 101: The Medical Device Handbook. Deutsche Bank Securities, Inc., North America, 1-70 (2002).
3. Ozaki Y, Violaris AG, Serruys PW. New stent technologies. Prog. Cardiovasc. Dia 39(2), 129-140 (1996).
4. Schatz RA, Baim DS, Leon M et al. Clincal experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 83, 148-161 (1991).
5. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part II. Circulation 106(22), 2859-2866 (2002).
6. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part I. Circulation 106(21), 2734-2740 (2002).
7. Gunn J, Cumberland D. Stent coatings and local drug deliver. State of the art. Eur. Heart J. 20(23), 1693-1700 (1999).
8. Hamon M, Lecluse E, Monassier JP, Grollier G, Potier JC. Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Drugs Aging 13(4), 291-301 (1998).
9. Colombo A, Karvouni E. Biodegradable stents: fulfilling the mission and stepping away. Circulation 102(4), 371-373 (2000).
10. Tanguay JF, Zidar JP, Phillips HR III, Stack RS. Current status of biodegradable stents. Cardiol Clin. 12(4), 699-713 (1994).
11. Rab ST, King SB, Roubin GS, Carlin S, Hearn JA, Douglas JSJ. Coronary aneurysms after stent placement: a suggestion of altered vessel wall healing in the presence of anti-inflammatory agents. J. Am. Coll. Cardiol. 18(6), 1524-1528 (1991).
12. Palmaz JC. Intravascular stents: tissue-stent interactions and design considerations. Am. J. Roentgenol 160(3), 613-618 (1993).
13. Yang XM, Manninen H, Matsi P, Soimakallio S. Percutaneous endovascular stenting: development, investigation and application. Eur. J. Radiol. 13(3), 161-173 (1991).
14. Beck A. A new balloon-expandable plastic endoprosthesis. Initial report of experience with the malleable thermostent. Radiologe 30(7), 347-350 (1990).
15. Susawa T, Shiraki K, Shimizu AY. Biodegradable intracoronary stents in adult dogs. J. Am. Coll. Cardiol. 21(Suppl. 1), 483A (1993).
16. Yoklavich M, Thatcher G, Sasken H. Vessel healing response to bioabsorbable implant. Fifth World Biomaterials Congress. May-June, Toronto, Canada (1996).
17. Kulkarni RK, Pani KC, Neuman C, Leonard F. Polylactic acid for surgical implants. Arch. Surg. 93, 839-843 (1966).
18. Kulkarni RK, Moore EG, Hegyeli AF, Leonard F. Biodegradable poly(lactic acid) polymers. J. Biomed. Mater. Rer. 5, 169-181 (1971).
19. Yolles S, Eldridge JE, Leafe TD, Woodland JHR, Blake DA, Meyer FJ. Long-acting delivery systems for narcotic antagonists. Adv Exp. Med Biol. 47, 177 (1973).
20. Suganuma J, Alexander H. Biological response of intramedullary bone to poly-L-lactic acid. J. Appl. Biomater. 4, 13-27 (1993).
21. Chu CR, Monosov AZ, Amiel D. In situ assessment of cell viability within biodegradable polylactic acid polymer matrices. Biomaterials 16(18), 1381-1384 (1995).
22. Mooney DJ, Baldwin DF, Suh NP, Vacanti JP, Langer R. Novel approach to fabricate porous sponges of poly (D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 17, 1417-1422 (1996).
23. Hooper KA, Macon ND, Kohn J. Comparative histological evaluation of new tyrosine-derived polymers and poly (L-lactic acid) as a function of polymer degradation. J. Biomed. Mater. Res. 41(3), 443-454 (1998).
24. Pariente JL, Kim BS, Atala A. In vitro biocompatibility assessment of naturally derived and synthetic biomaterials using normal human urothelial cells. J. Biomed. Mater. Res. 55(1), 33-39 (2001).
25. Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 102(4), 399-404 (2000).
26. Tamai H. Preclinical studies with tranilast and a tyrosine kinase inhibitor delivered from a PLLA bioerodable stent. Transcatheter Cardiovascular Therapeutics. Washington DC, USA (2002).
27. Pendharkar SM, James K, Kohn J. Iodinated derivatives of tyrosine-based polycarbonates: new radio-opaque degradable biomaterials. Annual Meeting of the Society for Biomaterials. CA, USA. Society for Biomaterials, Minneapolis, MN, USA, 386 (1998).
28. Zeltinger J, Schmid E, Brandom D, Bolikal D, Pesnell A, Kohn J. Advances in the development of coronary stents. Biomaterials Forum 26(1), 8-24 (2004).
29. Di Mario C, Griffiths H, Goktekin O et al. Drug-eluting bioabsorbable magnesium stent. J. Int. Cardiol. 17, 391-395 (2004).